Company / Interest Expense
VYNE Therapeutics Inc. Interest Expense History
FY2020-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$5.6M
FY2022
5-year range
$4.4M / $5.6M
FY2020-FY2022
Trend
+27.8%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $0 to $6M over the past 2 years.
Based on SEC 10-K filings.
$6M in FY2022.
Increased from $0 to $6M over the past 2 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, interest expense increased 27.8% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $5.6M | +27.8% |
| FY2021 | $4.4M | - |
| FY2020 | $0 | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026